Co-infection of Toxoplasma gondii with HBV in HIV-infected and uninfected pregnant women in Burkina Faso.
Toxoplasma gondii infections can induce serious complications in HIV-infected pregnant women, leading to miscarriage; favour the mother-to-child transmission of HBV and HIV and birth defects. The purposes of this study were: (1) to quantify IgM and IgG antibodies to Toxoplasma gondii in HIV-seropositive and seronegative pregnant women, (2) to identify hepatitis B antigens (HBsAg) in pregnant women and (3) to determine T. gondii and HBV co-infections among these patients. The study was conducted at Centre Medical Saint Camille, in Burkina Faso from January to June 2009. A total of 276 HIV-infected and uninfected pregnant women were included. All women had less than 32 weeks of amenorrhoea and were aged from 19 to 42 years. Toxoplasma gondii antibodies and HBsAg were detected using ELISA method. In addition, women freely agreed to answer a questionnaire. The results of our investigations revealed that, among these pregnant women, 38.8% were illiterates, 50.4% were housewives and only 5.4% were civil servants. Positive T. gondii-specific IgM (4.7%) and IgG (27.2%) were detected. In this study, we found that HIV-seropositive status seem to be associated with great prevalence rates of both T. gondii (31.9 vs. 22.5%) and HBV (13.0 vs. 5.8%). The elevated co-infection rate in HIV-positive women suggested that they are exposed to T. gondii and HBV infections prevalently because of their immune depression. Therefore, to reduce the prevalence of T. gondii and HBV among HIV-seropositive pregnant women, lamivudine could be included in their HEART and women should follow healthy lifestyle formation.
Ouermi
D
D
University of Ouagadougou, Ouagadougou, Burkina Faso.
Simpore
J
J
Belem
A M G
AM
Sanou
D S
DS
Karou
D S
DS
Ilboudo
D
D
Bisseye
C
C
Onadja
S M
SM
Pietra
V
V
Pignatelli
S
S
Gnoula
C
C
Nikiema
J B
JB
Kabre
G B
GB
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D002050:Burkina Faso / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000469:parasitology* / Q000821:virology*; D006509:Hepatitis B / Q000453:epidemiology / Q000276:immunology; D006511:Hepatitis B Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D015597:Pregnancy Complications, Parasitic; D011795:Surveys and Questionnaires; D014122:Toxoplasma / Q000276:immunology; D014123:Toxoplasmosis / Q000453:epidemiology / Q000276:immunology; D055815:Young Adult
D019380:Anti-HIV Agents; D006511:Hepatitis B Antigens; D019259:Lamivudine